Skip to main content

A “Universal” Influenza Vaccine through Synthetic, Dendritic Cell-Targeted, Self-Replicating RNA Vaccines

Objective

Although vaccination is the cornerstone of prophylaxis, current vaccines provide only moderate protection. Most employ inactivated or protein-based, including multimeric antigen, vaccines requiring annual updating. Their limited antigen loads provide limited capacity for inducing robust immune defences, without assurance that both humoral and cell mediated (CMI) responses, as well as durable immunity, will be induced. Replicating vaccines may provide several rounds of antigen production, increasing potential for humoral and CMI defence induction. Neither live, attenuated nor vector vaccines can be produced synthetically, being reliant on cell culture or egg production. They cannot be targeted to immune cells; interference from pre-existing immunity is also a risk.
Efficacious, synthetic vaccines would be the answer, as seen with self-replicating RNA replicon (RepRNA) technology – these replicate and translate without producing infectious progeny. RepRNA produced in vitro is combined with synthetic delivery vehicles targeting dendritic cell (DC) receptors –essential for efficient immune defences– with glycoconjugate ligands. The UniVax project promotes the first synergising of approaches with synthetic targeted delivery systems for RepRNA. The innovation integrates technologies of (i) RepRNA vaccines, (ii) lipoplexes (biodegradable lipid/adjuvant/RNA for cytosolic delivery), (iii) polyplexes (biodegradable, polysaccharide vehicles), (iv) glycoconjugates targeting DC receptors, (v) adjuvants with well-defined molecular targets and effector functions. This promotes efficacious mucosal and systemic responses, ensuring for the first time both humoral and CMI responses. Components developed in PANFLUVAC and Replixcel projects allow UniVax to create the first Universal” Flu vaccine prototypes. This innovative approach creates the first synthetic vaccine of its kind, promoting consortium SMEs to a unique position of world leaders.

Field of science

  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

EIDGENOESSISCHES DEPARTEMENT DES INNERN
Address
Inselgasse 1
3003 Bern
Switzerland
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
EU contribution
€ 1 181 117
Administrative Contact
Caroline De St. Simon (Mrs.)

Participants (10)

OZ BIOSCIENCES SAS
France
EU contribution
€ 535 900
Address
Parc Scientifique Et Technologique De Luminy Case 922 Bat Ccimp
13288 Marseille
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Olivier Zelphati (Dr.)
SYNTHAUR OOO
Russia
EU contribution
€ 187 360
Address
Ul Miklukho Maklaya 16/10
117997 Moskva
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Nicolai Bovin (Prof.)
VITAMFERO SA
France
EU contribution
€ 439 800
Address
Rue Andre Le Notre 8 Angers Technopole
49000 Angers
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Edouard Sèche (Dr.)
AMVAC RESEARCH GMBH
Germany
EU contribution
€ 468 640
Address
Lochhamer Strasse 29 A
82152 Martinsried
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Marian Wiegand (Dr.)
MEDITOX S.R.O
Czechia
EU contribution
€ 413 277
Address
Pod Zamkem 279
28125 Konarovice
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Martin Slais (Dr.)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
EU contribution
€ 467 430
Address
Rue Michel Ange 3
75794 Paris
Activity type
Research Organisations
Administrative Contact
Camille Sèze-Goismier (Dr.)
THE UNIVERSITY OF MANCHESTER
United Kingdom
EU contribution
€ 683 534
Address
Oxford Road
M13 9PL Manchester
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Claire Faichnie (Ms.)
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany
EU contribution
€ 618 628
Address
Inhoffenstrasse 7
38124 Braunschweig
Activity type
Research Organisations
Administrative Contact
Michael Strätz (Dr.)
UNIVERSITETET I BERGEN
Norway
EU contribution
€ 735 771
Address
Museplassen 1
5020 Bergen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Liv-Grethe Gudmundsen (Ms.)
TP21 GMBH
Germany
EU contribution
€ 268 000
Address
Luisenstrasse 14
10117 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Petra Zalud (Dr.)